MedWatch

Virogates boss excited about IPO: Will speed up sale of blood test

The diagnostics company Virogates wants to bring in more than DKK 60 million (USD 9.4 million) on the stock exchange, which will be used to boost sales of the company's blood test. The goal is to have 40 paying customers in two years says CEO.

Jakob Knudsen, CEO of Virogates. | Foto: Virogates

It was a happy CEO from Danish company Virogates that could unveil the prospectus of an IPO in Copenhagen on Monday.

The company expects to bring in between DKK 60 and 75 million (USD 9.4 to 11.8 million) from the listing, and the majority of that amount has already been secured through a number of investors that, among others, include Vækstfonden, the Danish Growth Fund.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Sydbank-analytiker: Positivt at Bavarian Nordic-aktiesalg klares hurtigt

Det er positivt, vurderer analytiker i Sydbank, at Bavarian Nordic allerede om en uge regner med at kunne præsentere resultatet af det udbud, selskabet tidligere mandag offentliggjorde, som skal sikre finansiering af et fase 3-studie med en vaccinekandidat mod RS-virus i første halvår 2022.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier